Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CoWin Biosciences

Request full access

Provides high-quality biology reagents in life science research and molecular diagnostics field

Watertown, United StatesFounded 2006Biotech & Life Sciences

About CoWin Biosciences

CoWin Biosciences, registered as Jiangsu CoWin Biotech Co., Ltd., is a publicly traded entity on the Shanghai STAR Market that operates at the forefront of the life sciences sector, specifically in molecular diagnostics. Established in 2007, the company has built a considerable presence by providing high-quality biological reagents and developing core technologies in-house. The company's founder and chairwoman, Wang Chunxiang, holds a Ph.D. from UCLA's Department of Pathology and has leveraged her extensive background to guide the company's research and development efforts. She was a primary author for China's technical standards for nucleic acid detection kit quality evaluation, underscoring the firm's deep technical expertise.

The company's business model is vertically integrated, covering key stages of the molecular detection value chain, including enzyme raw materials, nucleic acid preservation, sample pre-treatment, and diagnostic kit production. This structure allows CoWin to serve a diverse clientele, from life science researchers to manufacturers of gene detection and molecular diagnostic reagents, by offering both off-the-shelf products and customized OEM solutions. Revenue is generated through the sale of its extensive product portfolio, which now exceeds 1,000 items. A significant milestone was its Initial Public Offering on October 25, 2022, which raised approximately $156 million (¥1.14 billion). These funds are earmarked for expanding production capacity, enhancing its marketing network both in China and globally, and advancing its molecular diagnostics R&D pipeline.

CoWin Biosciences' product suite is comprehensive, addressing several critical areas of molecular biology. Key categories include sample collection and stabilization, nucleic acid extraction and purification, PCR/qPCR reagents, and solutions for Next-Generation Sequencing (NGS) library preparation. The company has developed specialized products like cfDNA storage tubes for liquid biopsy applications and various kits for detecting infectious diseases. Its offerings are pivotal for applications in oncology, infectious disease diagnostics, and prenatal testing. With a strategic focus on expanding its molecular diagnostics segment, the firm is actively developing new tests for digestive diseases like Helicobacter pylori and colorectal cancer, as well as rapid diagnostics for respiratory pathogens. The company holds numerous domestic and international certifications, including ISO 9001:2008 and ISO 13485:2003, with its products cited in over 1,000 peer-reviewed publications.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
25.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Sep 2020 $36M $143M Green Pine Capital · Share Capital · Addor Capital —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

CoWin Biosciences website traffic

Latest recorded traffic for CoWin Biosciences is 1.2K monthly website visits, up 990.9% over the last three months. CoWin Biosciences's team grew 0% over the past year.

Latest monthly visits1.2K 3-month web change+990.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

CoWin Biosciences in the Watertown ecosystem

Live from Dealroom

The CoWin Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Addor Capital
  • Green Pine Capital
  • Share Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China60%
🇺🇸 United States40%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CoWin Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CoWin Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.